Patents by Inventor Kevin McDonnell

Kevin McDonnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250064950
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to P-selectin. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are binders of P-selectin. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by a cell adhesion molecule, such as P-selectin, including vaso-occlusive crisis and sickle cell disease-related conditions, cancer, or COVID-19.
    Type: Application
    Filed: October 21, 2024
    Publication date: February 27, 2025
    Inventors: Kevin McDonnell, Gemma Mudd, Michael Skynner, Sophie Watcham
  • Publication number: 20250059236
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Application
    Filed: June 13, 2024
    Publication date: February 20, 2025
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Elizabeth Mudd, Peter Park
  • Patent number: 12150998
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to P-selectin. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are binders of P-selectin. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by a cell adhesion molecule, such as P-selectin, including vaso-occlusive crisis and sickle cell disease-related conditions, cancer, or COVID-19.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: November 26, 2024
    Assignee: BicycleTx Limited
    Inventors: Kevin McDonnell, Gemma Mudd, Michael Skynner, Sophie Watcham
  • Publication number: 20240336656
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Application
    Filed: January 26, 2024
    Publication date: October 10, 2024
    Inventors: Gemma MUDD, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
  • Patent number: 12049520
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: July 30, 2024
    Assignee: BicycleTx Limited
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Elizabeth Mudd, Peter Park
  • Patent number: 11970553
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: April 30, 2024
    Assignee: BicycleTx Limited
    Inventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
  • Patent number: 11679080
    Abstract: The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: June 20, 2023
    Assignee: TGX SOFT CHEW, LLC
    Inventors: Kevin McDonnell, Joanna Rossi, Scott Eccles, Gueorgui Puchkarov
  • Patent number: 11613560
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: March 28, 2023
    Assignee: BicycleTx Limited
    Inventors: Tom Li Stephen, Kevin McDonnell, Nicholas Keen, Liuhong Chen, Helen Harrison, Peter U. Park, Michael Skynner, Harvey Che
  • Patent number: 11608871
    Abstract: A shock absorbing system for force attenuation, impact modification or reduction, employs an envelope having a chamber containing a first working fluid, the envelope deformable in response to the impulse to attenuate impact force. A plurality of resilient supplemental absorber elements dispersed within the chamber. The plurality of resilient supplemental absorber elements are deformable in response to the force to assist in attenuating impact force and provide additional resilient restoring force to return the envelope to a pre-impact shape. In alternative implementations, a unitary cell for energy dissipation employs an envelope having a chamber containing a first working fluid and an inner element contained within the chamber and having an inner chamber containing a second working fluid.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: March 21, 2023
    Inventors: Kevin McDonnell, Alexandra McDonnell
  • Patent number: 11542304
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: January 3, 2023
    Inventors: Liuhong Chen, Rachid Lani, Kevin Mcdonnell, Gemma Mudd, Peter U. Park, Punit Upadhyaya
  • Patent number: 11478421
    Abstract: The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: October 25, 2022
    Assignee: TGX SOFT CHEW, LLC
    Inventors: Kevin McDonnell, Joanna Rossi, Scott Eccles, Gueorgui Puchkarov
  • Patent number: 11459032
    Abstract: A trailer assembly with improved lateral support structure and steering system control of the axial wheels on a front elongated trailer and a rear elongated trailer to remain in a collinear following configuration to carry elongated loads extending over the extended lengths of the combination of the front elongated trailer and the rear elongated trailer and allow ready turning control.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: October 4, 2022
    Assignee: Slingshot Haulage Pty Ltd
    Inventors: Leigh Dehne, Kevin McDonnell
  • Publication number: 20220306694
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 29, 2022
    Inventors: Gemma MUDD, Punit Upadhyaya, Kevin Mcdonnell
  • Patent number: 11453703
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: September 27, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya, Gemma Mudd
  • Patent number: 11396530
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: July 26, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Patent number: 11332500
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 17, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell
  • Patent number: 11312749
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: April 26, 2022
    Assignee: BicycleTx Limited
    Inventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
  • Patent number: 11306123
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: April 19, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
  • Patent number: 11261214
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: March 1, 2022
    Assignee: BicycleTx Limited
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Mudd, Peter Park
  • Patent number: 11215257
    Abstract: A shock absorbing system for impact energy dissipation employs removable unitary cells of compressible members in communication with a reservoir and containing a first working fluid. Resilient structural members may be placed intermediate the compressible members to deform responsive to compression to provide both energy dissipation and resilient recovery of the compression cylinders to their uncompressed state.
    Type: Grant
    Filed: December 16, 2018
    Date of Patent: January 4, 2022
    Inventor: Kevin McDonnell